Skip to main content
. Author manuscript; available in PMC: 2013 Aug 5.
Published in final edited form as: Mol Pharm. 2012 Apr 6;9(5):1118–1125. doi: 10.1021/mp2003835

Figure 1.

Figure 1

Lip{LLO,OVA,ISS} induces IL-12 secretion and MHC Class I-restricted presentation of OVA-specific peptides by BMM. (A) BMM were treated with sol{ISS} (4.7 μg/mL) for 24 h or lip{LLO,OVA} (10 μg/mL OVA; 0 μg/mL ISS) or lip{LLO,OVA,ISS} (10 μg/mL OVA; 4.7 μg/mL ISS) for 2 h. After 2 h incubation, the cells were washed and further incubated for 22 h. Cell culture supernatants were analyzed for IL-12 secretion by ELISA. (B) BMM were pulsed with lip{LLO,OVA} or lip{LLO,OVA,ISS} (10 μg/mL OVA) for 2 h. Cells were washed, further incubated for 3 h and fixed; B3Z cells were added. After 15 h incubation with B3Z cells, the level of presentation of SIINFEKL OVA-CD8 peptide by BMM to B3Z cells as monitored by the conversion of CPRG substrate to chlorophenol red in the activated B3Z cells. Cells were pulsed with SIINFEKL peptide (90 nM) as a positive control, and OD values were 1.28. Data represent the average of triplicates ± S.D and are representative of results from multiple independent experiments that were repeated.